Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution

Emerging Microbes and Infections

Volumn 3, Issue 11, 2014, Pages e78-

  Zhang, Xiaonan ^a   Song, Zhigang ^a   He, Jing ^a   Yen, Hui Ling ^b   Li, Jianhua ^c   Zhu, Zhaoqin ^a   Tian, Di ^a   Wang, Wei ^a   Xu, Lei ^a   Guan, Wencai ^a   Liu, Yi ^a   Wang, Sen ^a,c   Shi, Bisheng ^a   Zhang, Wanju ^a   Qin, Boyin ^a   Cai, Jialin ^a   Wan, Yanmin ^a   Xu, Chunhua ^a   Ren, Xiaonan ^a   Chen, Haili ^a   Liu, Lu ^a   Yang, Yuqin ^a   Zhou, Xiaohui ^a   Zhou, Wenjiang ^a   Xu, Jianqing ^a,c   Zhang, Xiaoyan ^a,c   Peiris, Malik ^b   Hu, Yunwen ^a   Yuan, Zhenghong ^c   more..

^a FUDAN UNIVERSITY   (China)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

H7N9; Influenza virus; Neuraminidase; Oseltamivir; Peramivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; FAVIPIRAVIR; NITAZOXANIDE; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; SIALIDASE INHIBITOR; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; ATTENUATION; CASE REPORT; CELL ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; FEMALE; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A; INFLUENZA A (H7N9); INFLUENZA VIRUS A H7N9; LETHALITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SYMPTOM; VIRUS CULTURE; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTANT; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE; WILD TYPE;

ANIMALIA; MUS; ORTHOMYXOVIRIDAE;

EID: 84931260499     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2014.80     Document Type: Article

References (24)

1. Gao R, Cao B, Hu Y et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368: 1888-1897.
2. Lam TT-Y, Wang J, Shen Y et al. The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature 2013; 502: 241-244.
3. Wu A, Su C, Wang D et al. Sequential reassortments underlie diverse influenza H7N9 genotypes in China. Cell Host Microbe 2013; 14: 446-452.
4. Liu D, Shi W, Shi Y et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 2013; 381: 1926-1932.
5. Wang D, Yang L, Gao R et al. Genetic tuning of the novel avian influenza A(H7N9) virus during interspecies transmission, China, 2013. Euro Surveill 2014; 19. pii: 20836
6. Ren L, Yu X, Zhao B et al. Infection with possible precursor of avian influenza A(H7N9) virus in a child, China, 2013. Emerg Infect Dis 2014; 20: 1362-1365.
7. McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses 2013; 7(Suppl 1): 25-36.
8. Yen HL, Herlocher LM, Hoffmann E et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005; 49: 4075-4084.
9. Yen HL, McKimm-Breschkin JL, Choy KT et al. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. mBio 2013; 4. pii: e00396-13
10. Hu Y, Lu S, Song Z et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381: 2273-2279.
11. Lin PH, Chao TL, Kuo SW et al. Virological, serological, and antiviral studies in an imported human case of avian influenza A(H7N9) virus in Taiwan. Clin Infect Dis 2014; 58: 242-246.
12. Kageyama T, Fujisaki S, Takashita E et al. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill 2013; 18: 20453.
13. Wang W, Song Z, Guan W et al. PCR for detection of oseltamivir resistance mutation in influenza A(H7N9) virus. Emerg Infect Dis 2014; 20: 847-849.
14. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681.
15. Chou TC. Drug combination studies and their synergy quantification using the Chou- Talalay method. Cancer Res 2010; 70: 440-446.
16. Zhu Z, Yang Y, Feng Y et al. Infection of inbred BALB/c and C57BL/6 and outbred Institute of Cancer Research mice with the emerging H7N9 avian influenza virus. Emerg Microbes Infect 2013; 2: e50.
17. Gao HN, Lu HZ, Cao B et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368: 2277-2285.
18. Liu X, Li T, Zhen YF, Wong KW, Lu SH, Lu HZ. Poor responses to oseltamivir treatment in a patient with influenza a (H7N9) infection. Emerg Microbes Infect 2013; 2: e27.
19. Watanabe T, Kiso M, Fukuyama S et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 2013; 501: 551-555.
20. Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubareva LV. R292K substitution and drug susceptibility of influenza A(H7N9) viruses. Emerg Infect Dis 2013; 19: 1521-1524.
21. Rong H, Schmolke M, Leyva-Grado VH et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun 2013; 4: 2854.
22. Marjuki H, Mishin VP, Chesnokov AP et al. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality. J Infect Dis 2014; 210: 435-440.
23. Yen HL, Zhou J, Choy KT et al. The R292K mutation that confers resistance to neuraminidase inhibitors leads to competitive fitness loss of A/Shanghai/1/2013 (H7N9) influenza virus in ferrets. J Infect Dis 2014; June 20. doi:10.1093/infdis/jiu353.
24. Baranovich T, Webster RG, Govorkova EA. Fitness of neuraminidase inhibitor-resistant influenza A viruses. Curr Opin Virol 2011; 1: 574-581.